IL237340A0 - Anxiolytic composition, formulation and method of use - Google Patents

Anxiolytic composition, formulation and method of use

Info

Publication number
IL237340A0
IL237340A0 IL237340A IL23734015A IL237340A0 IL 237340 A0 IL237340 A0 IL 237340A0 IL 237340 A IL237340 A IL 237340A IL 23734015 A IL23734015 A IL 23734015A IL 237340 A0 IL237340 A0 IL 237340A0
Authority
IL
Israel
Prior art keywords
anxiety
formulation
preparation
anxiety preparation
Prior art date
Application number
IL237340A
Other languages
English (en)
Hebrew (he)
Original Assignee
Weg Stuart L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Weg Stuart L filed Critical Weg Stuart L
Publication of IL237340A0 publication Critical patent/IL237340A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL237340A 2012-08-23 2015-02-22 Anxiolytic composition, formulation and method of use IL237340A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261692380P 2012-08-23 2012-08-23
PCT/US2013/056424 WO2014031975A1 (en) 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use

Publications (1)

Publication Number Publication Date
IL237340A0 true IL237340A0 (en) 2015-04-30

Family

ID=50148531

Family Applications (1)

Application Number Title Priority Date Filing Date
IL237340A IL237340A0 (en) 2012-08-23 2015-02-22 Anxiolytic composition, formulation and method of use

Country Status (11)

Country Link
US (4) US20140057988A1 (OSRAM)
EP (2) EP3878442A1 (OSRAM)
JP (2) JP6722453B2 (OSRAM)
KR (1) KR20150096370A (OSRAM)
CN (1) CN104902883A (OSRAM)
AU (1) AU2013305580A1 (OSRAM)
BR (1) BR112015003796A2 (OSRAM)
IL (1) IL237340A0 (OSRAM)
MX (1) MX2015002378A (OSRAM)
SG (1) SG11201501292UA (OSRAM)
WO (1) WO2014031975A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045982T2 (hu) * 2013-03-15 2020-01-28 Janssen Pharmaceutica Nv S-Ketamin-hidroklorid gyógyászati kompozíció
ES2755809T3 (es) 2013-03-15 2020-04-23 Janssen Pharmaceutica Nv Composición farmacéutica de hidrocloruro de S-ketamina
KR20150142012A (ko) 2013-04-12 2015-12-21 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
RS62516B1 (sr) 2013-09-13 2021-11-30 Univ Chiba Nat Univ Corp Primena r-ketamina i njegove soli kao farmaceutskih proizvoda
JP6545788B2 (ja) 2014-08-13 2019-07-17 ヤンセン ファーマシューティカ エヌ.ベー. うつ病の治療方法
JP6757537B2 (ja) * 2014-08-29 2020-09-23 公益財団法人ヒューマンサイエンス振興財団 神経疾患モデル動物の製造方法及び神経疾患モデル動物
WO2016044150A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
EP3085366A1 (en) * 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN107949379A (zh) * 2015-05-22 2018-04-20 维斯塔津治疗公司 L‑4‑氯代犬尿氨酸的治疗用途
JP6845162B2 (ja) 2015-06-27 2021-03-17 シェノックス・ファーマシューティカルズ・エルエルシー ケタミン経皮送達システム
CN105249531A (zh) * 2015-08-06 2016-01-20 云南中烟工业有限责任公司 一种金丝楠木提取物的制备方法及其应用
CA2997187C (en) * 2015-09-08 2024-02-20 The Children's Hospital Of Philadelphia Methods of diagnosing and treating tourette syndrome
WO2017087691A1 (en) * 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
FR3075038B1 (fr) * 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
BR112020012473A2 (pt) 2017-12-22 2020-11-24 Janssen Pharmaceuticals, Inc. escetamina para o tratamento da depressão
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
EP3753557B1 (en) 2018-02-15 2025-11-05 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
CA3099293A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
US12090145B2 (en) * 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
JP7458366B2 (ja) 2019-02-22 2024-03-29 ハリマ化成株式会社 固形ろう付け材の塗布方法、塗布物の製造方法、塗布装置、および、ロール形状の固形ろう付け材
CN114126595A (zh) 2019-03-05 2022-03-01 杨森制药公司 用于治疗抑郁症的艾司氯胺酮
EP3968977A4 (en) * 2019-05-15 2023-01-11 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS AGAINST AFFECTIVE DISORDERS INDUCED BY STRESS AND THEIR ASSOCIATED SYMPTOMS
PT3976012T (pt) * 2019-05-31 2024-04-09 Afyx Therapeutics As Administração intranasal de cetamina a doentes com cefaleia em salvas
US20230064327A1 (en) 2020-01-22 2023-03-02 Seelos Therapeutics, Inc. Reducing side effects of nmda antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
CN101765582A (zh) * 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 氘标记的氯胺酮
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder

Also Published As

Publication number Publication date
JP6722453B2 (ja) 2020-07-15
MX2015002378A (es) 2015-09-25
AU2013305580A1 (en) 2015-04-09
EP2887930A4 (en) 2016-03-23
EP2887930A1 (en) 2015-07-01
WO2014031975A1 (en) 2014-02-27
BR112015003796A2 (pt) 2017-07-04
KR20150096370A (ko) 2015-08-24
JP2016501828A (ja) 2016-01-21
US20250255834A1 (en) 2025-08-14
US20140057988A1 (en) 2014-02-27
SG11201501292UA (en) 2015-05-28
US20180235906A1 (en) 2018-08-23
JP6771512B2 (ja) 2020-10-21
EP3878442A1 (en) 2021-09-15
JP2018162302A (ja) 2018-10-18
CN104902883A (zh) 2015-09-09
US20220160655A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
IL237340A0 (en) Anxiolytic composition, formulation and method of use
KR101849656B9 (ko) 디스플레이 장치의 제조방법, 디스플레이 장치의 제조장치
BR112015003354A8 (pt) métodos e composições de microcápsula
DK3777840T3 (da) Rna-formulering til immunterapi
FI20125229L (fi) Menetelmä, laite ja järjestely ihmismäärän arvioimiseksi
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2804587T3 (da) Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
DK2872153T3 (da) Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
BR112015003227A2 (pt) processos de clicoconjugação e composições
DK2917763T3 (da) Lidar-målesystem og lidar-målefremgangsmåde
DK2900657T3 (da) Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
DK2858671T3 (da) Antistofformulering
DK2890397T3 (da) Antiprolactinreceptor-antistofformulering
CU24158B1 (es) Método de obtención de 1-kestosa
BR112014028282A2 (pt) composição cosmética anidra e método cosmético
EP2810070A4 (en) EXTRACTION OF MYCOTOXINES
EP2925338A4 (en) LYOPHILIZED FORMULATION OF TAT-NR2B9C
BR112014020677A2 (pt) composições de farinha de milho e métodos de produção
EP2866154A4 (en) METHOD AND DEVICE FOR OBTAINING A RESOURCE
BR112015013025A2 (pt) composição cosmética fotorreticulável, método de esmalte e conjunto
PT2825039T (pt) Formulação de ibuprofeno injetável
BR112014017038A8 (pt) método, e aparato
BR112015007217A2 (pt) compostos e usos do composto
BR112015002542A2 (pt) método de caracterização de um objeto
BR112014026880A2 (pt) composição de sensibilização e método de uso